Cardiovascular diseases are the leading cause of mortality and morbidity worldwide. Histone deacetylases (HDACs) play an important role in the epigenetic regulation of genetic transcription in response to stress or pathological conditions. HDACs interact with a complex co-regulatory network of transcriptional regulators, deacetylate histones or non-histone proteins, and modulate gene expression in the heart. The selective HDAC inhibitors have been considered to be a critical target for the treatment of cardiac disease, especially for ameliorating cardiac dysfunction. In this review, we discuss our current knowledge of the cellular and molecular basis of HDACs in mediating cardiac development and hypertrophy and related pharmacologic interventions in heart disease.
ChangCPBruneauBG.Epigenetics and cardiovascular development. Annu Rev Physiol2012;
74:41–68
10.
WebsterALYanMSMarsdenPA.Epigenetics and cardiovascular disease. Can J Cardiol2013;
29:46–57
11.
ShirodkarAVMarsdenPA.Epigenetics in cardiovascular disease. Curr Opin Cardiol2011;
26:209–15
12.
ChaturvediPTyagiSC.Epigenetic mechanisms underlying cardiac degeneration and regeneration. Int J Cardiol2014;
173:1–11
13.
TingareAThienpontBRoderickHL.Epigenetics in the heart: the role of histone modifications in cardiac remodelling. Biochem Soc Trans2013;
41:789–96
14.
StenvinkelPCarreroJJAxelssonJLindholmBHeimburgerOMassyZ.Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?Clin J Am Soc Nephrol2008;
3:505–21
15.
AsrihMSteffensS.Emerging role of epigenetics and miRNA in diabetic cardiomyopathy. Cardiovasc Pathol2013;
22:117–25
16.
BreitlingLP.Current genetics and epigenetics of smoking/tobacco-related cardiovascular disease. Arterioscler Thromb Vasc Biol2013;
33:1468–72
17.
DuthieSJ.Epigenetic modifications and human pathologies: cancer and CVD. Proc Nutr Soc2011;
70:47–56
18.
DuyguBPoelsEMda Costa MartinsPA.Genetics and epigenetics of arrhythmia and heart failure. Front Genet2013;
4:219
BishtonMKenealyMJohnstoneRRasheedWMiles PrinceH.Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents. Expert Rev Anticancer Ther2007;
7:1439–49
21.
SwaminathanVReddyBARuthrotha SelviBSukanyaMSKunduTK.Small molecule modulators in epigenetics: implications in gene expression and therapeutics. Subcell Biochem2007;
41:397–428
22.
WangXHayesJJ.Physical methods used to study core histone tail structures and interactions in solution. Biochem Cell Biol2006;
84:578–88
23.
GrozingerCMHassigCASchreiberSL.Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc Natl Acad Sci USA1999;
96:4868–73
24.
de RuijterAJvan GennipAHCaronHNKempSvan KuilenbergA.Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J2003;
370:737–49
25.
YangXJSetoE.The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol2008;
9:206–18
26.
BlanderGGuarenteL.The Sir2 family of protein deacetylases. Annu Rev Biochem2004;
73:417–35
27.
HaberlandMMontgomeryRLOlsonEN.The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet2009;
10:32–42
28.
ThiagalingamSChengKHLeeHJMinevaNThiagalingamAPonteJF.Histone deacetylases: unique players in shaping the epigenetic histone code. Ann NY Acad Sci200:84–100
29.
LiJLinQWangWWadePWongJ.Specific targeting and constitutive association of histone deacetylase complexes during transcriptional repression. Genes Dev2002;
16:687–92
30.
FischleWKiermerVDequiedtFVerdinE.The emerging role of class II histone deacetylases. Biochem Cell Biol2001;
79:337–48
31.
MartinMKettmannRDequiedtF.Class IIa histone deacetylases: regulating the regulators. Oncogene2007;
26:5450–67
32.
FischleWDequiedtFHendzelMJGuentherMGLazarMAVoelterWVerdinE.Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell2002;
9:45–57
33.
HornigEHepptMVGrafSARuzickaTBerkingC.Inhibition of histone deacetylases in melanoma-a perspective from bench to bedside. Exp Dermatol2016;
25:831–8
34.
McKinseyTA.The biology and therapeutic implications of HDACs in the heart. Handb Exp Pharmacol2011;
206:57–78
35.
van ZonneveldAJ.Molecular biology and genetics in cardiovascular research: highlights of 2002. Neth J Med2003;
61:28–34
36.
LehmannLHWorstBCStanmoreDABacksJ.Histone deacetylase signaling in cardioprotection. Cell Mol Life Sci2014;
7:1673–90
37.
EomGHKookH.Posttranslational modifications of histone deacetylases: implications for cardiovascular diseases. Pharmacol Ther2014;
143:168–80
38.
BorradaileNMPickeringJG.NAD(+), sirtuins, and cardiovascular disease. Curr Pharm Des2009;
15:110–7
39.
GaoLCuetoMAAsselbergsFAtadjaP.Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem2002;
277:25748–55
40.
KomuroI.Molecular mechanism of cardiac hypertrophy and development. Jpn Circ J2001;
65:353–8
41.
CharronFNemerM.GATA transcription factors and cardiac development. Semin Cell Dev Biol1999;
10:85–91
42.
MaPSchultzRM.Histone deacetylase 1 (HDAC1) regulates histone acetylation, development, and gene expression in preimplantation mouse embryos. Dev Biol2008;
319:110–20
43.
MontgomeryRLDavisCAPotthoffMJ.Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev2007;
21:1790–802
44.
HoxhaELambersEXieHDe AndradeAKrishnamurthyPWasserstromJARamirezVThalMVermaSKSoaresMBKishoreR.Histone deacetylase 1 deficiency impairs differentiation and electrophysiological properties of cardiomyocytes derived from induced pluripotent cells. Stem Cells2012;
30:2412–22
45.
HoxhaELambersEWasserstromJAMackieARamirezVAbramovaTVermaSKKrishnamurthyKishoreR.Elucidation of a novel pathway through which HDAC1 controls cardiomyocyte differentiation through expression of SOX-17 and BMP2. PLoS One2012;
7:e45046
46.
LiuZLiTLiuYJiaZLiYZhangCChenPMaKAffaraNZhouC.WNT signaling promotes Nkx2.5 expression and early cardiomyogenesis via downregulation of Hdac1. Biochim Biophys Acta2009;
1793:300–11
47.
DoveyOMFosterCTCowleySM.Histone deacetylase 1 (HDAC1), but not HDAC2, controls embryonic stem cell differentiation. Proc Natl Acad Sci USA2010;
107:8242–7
48.
KaichiSTakayaTMorimotoTSunagawaYKawamuraTOnoKShimatsuABabaSHeikeTNakahataTHasegawaK.Cyclin-dependent kinase 9 forms a complex with GATA4 and is involved in the differentiation of mouse ES cells into cardiomyocytes. J Cell Physiol2011;
226:248–54
49.
KaramboulasCSwedaniAWardCAl-MadhounASWiltonSBoisvenueSRidgewayAGSkerjancIS.HDAC activity regulates entry of mesoderm cells into the cardiac muscle lineage. J Cell Sci2006;
119:4305–14
50.
KawamuraTOnoKMorimotoTWadaHHiraiMHidakaKMorisakiTHeikeTNakahataTKitaTHasegawaK.Acetylation of GATA-4 is involved in the differentiation of embryonic stem cells into cardiac myocytes. J Biol Chem2005;
280:19682–8
51.
LuDFYaoYSuZZZengZHXingXWHeZYZhangC.Downregulation of HDAC1 is involved in the cardiomyocyte differentiation from mesenchymal stem cells in a myocardial microenvironment. PLoS One2014;
9:e93222
52.
WangMYuQWangLGuH.Distinct patterns of histone modifications at cardiac-specific gene promoters between cardiac stem cells and mesenchymal stem cells. Am J Physiol, Cell Physiol2012;
304:C1080–90
53.
FengCZhuJZhaoLLuTZhangWLiuZTianJ.Suberoylanilide hydroxamic acid promotes cardiomyocyte differentiation of rat mesenchymal stem cells. Exp Cell Res2009;
315:3044–51
54.
TrivediCMLuMMWangQEpsteinJA.Transgenic overexpression of Hdac3 in the heart produces increased postnatal cardiac myocyte proliferation but does not induce hypertrophy. J Biol Chem2008;
283:26484–9
55.
TrivediCMLuoYYinZZhangMZhuWWangTFlossTGoettlicherMRNoppingerPWurstWFerrariVAAbramsCSGruberPJEpsteinJA.Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med2007;
13:324–31
56.
LewandowskiSLJanardhanHPSmeeKMBachmanMSunZLazarMATrivediCM.Histone deacetylase 3 modulates Tbx5 activity to regulate early cardiogenesis. Hum Mol Genet2014;
23:3801–9
57.
ChangSMcKinseyTAZhangCLRichardsonJAHillJAOlsonEN.Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol2004;
24:8467–76
58.
AkazawaHKomuroI.Roles of cardiac transcription factors in cardiac hypertrophy. Circ Res2003;
92:1079–88
59.
OlsonENBacksJMcKinseyTA.Control of cardiac hypertrophy and heart failure by histone acetylation/deacetylation. Novartis Found Symp2006;
274:3–12
60.
LaggerGO’CarrollDRemboldMKhierHTischlerJWeitzerGSchuettengruberBHauserCBrunmeirRJenuweinTSeiserC.Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. Embo J2002;
21:2672–81
61.
KuwaharaKSaitoYTakanoMAraiYYasunoSNakagawaYTakahashiNAdachiYTakemuraGHorieMMiyamotoYMorisakiTKuratomiSNomaAFujiwaraHYoshimasaYKinoshitaHKawakamiRKishimotoINakanishiMUsamiSSaitoYHaradaMNakaoK.NRSF regulates the fetal cardiac gene program and maintains normal cardiac structure and function. Embo J2003;
22:6310–21
62.
FergusonBSHarrisonBCJeongMYReidBGWempeMFWagnerFFHolsonEBMcKinseyTA.Signal-dependent repression of DUSP5 by class I HDACs controls nuclear ERK activity and cardiomyocyte hypertrophy. Proc Natl Acad Sci USA2013;
110:9806–11
63.
KeeHJEomGHJoungHShinSKimJRChoYKChoeNSimBWJoDJeongMHKimKKSeoJSKookH.Activation of histone deacetylase 2 by inducible heat shock protein 70 in cardiac hypertrophy. Circ Res2008;
103:1259–69
64.
EomGHNamYSOhJGChoeNMinHKYooEKKangGNguyenVHMinJJKimJKLeeIKBassel-DubyROlsonENParkWJKookH.Regulation of acetylation of histone deacetylase 2 by p300/CBP-associated factor/histone deacetylase 5 in the development of cardiac hypertrophy. Circ Res2014;
114:1133–43
65.
EomGHChoYKKoJHShinSChoeNKimYJoungHKimHSNamKIKeeHJKookH.Casein kinase-2alpha1 induces hypertrophic response by phosphorylation of histone deacetylase 2 S394 and its activation in the heart. Circulation2011;
123:2392–403
ZhuWTrivediCMZhouDYuanLLuMMEpsteinJA.Inpp5f is a polyphosphoinositide phosphatase that regulates cardiac hypertrophic responsiveness. Circ Res2009;
105:1240–7
69.
CoxEJMarshSA.Exercise and diabetes have opposite effects on the assembly and O-GlcNAc modification of the mSin3A/HDAC1/2 complex in the heart. Cardiovasc Diabetol2013;
9:101
70.
WengYJKuoWWKuoCHTungKCTsaiCHLinJATsaiFJHsiehDJYHuangCYHwangJM.BNIP3 induces IL6 and calcineurin/NFAT3 hypertrophic-related pathways in H9c2 cardiomyoblast cells. Mol Cell Biochem2010;
345:241–7
71.
GlennDJWangFChenSNishimotoMGardnerDG.Endothelin-stimulated human B-type natriuretic peptide gene expression is mediated by yin yang 1 in association with histone deacetylase 2. Hypertension2009;
53:549–55
72.
MontgomeryRLPotthoffMJHaberlandMQiXMatsuzakiSHumphriesKMRichardsonJABassel-DubyROlsonEN.Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J Clin Invest2008;
118:3588–97
73.
DavisFJGuptaMCamoretti-MercadoBSchwartzRJGuptaMP.Calcium/calmodulin-dependent protein kinase activates serum response factor transcription activity by its dissociation from histone deacetylase, HDAC4. Implications in cardiac muscle gene regulation during hypertrophy. J Biol Chem2003;
278:20047–58
74.
ZhangCLMcKinseyTAChangSAntosCLHillJAOlsonEN.Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell2002;
110:479–88
75.
EllisJJValenciaTGZengHRobertsLDDeatonRAGrantSR.CaM kinase IIdeltaC phosphorylation of 14-3-3beta in vascular smooth muscle cells: activation of class II HDAC repression. Mol Cell Biochem2003;
242:153–61
76.
OliveiraRSFerreiraJCGomesERPaixaoNARolimNPLMedeirosAGuatimosimSBrumPC.Cardiac anti-remodelling effect of aerobic training is associated with a reduction in the calcineurin/NFAT signalling pathway in heart failure mice. J Physiol (Lond)2009;
587:3899–910
77.
McKinseyTAZhangCLOlsonEN.Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5. Proc Natl Acad Sci USA2000;
97:14400–5
78.
McKinseyTAZhangCLLuJOlsonEN.Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature2000;
408:106–11
79.
PassierRZengHFreyNNayaFJMcKinseyTAOverbeekPRichardsonJAGrantSROlsonEN.CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. J Clin Invest2000;
105:1395–406
80.
VegaRBHarrisonBCMeadowsERobertsCRPapstPJOlsonENMcKinseyTA.Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol Cell Biol2004;
24:8374–85
81.
HarrisonBCKimMSvan RooijEPlatoCFPapstPJVegaRBMcAnallyJARichardsonJABassel-DubyROlsonENMcKinseyTA.Regulation of cardiac stress signaling by protein kinase d1. Mol Cell Biol2006;
26:3875–88
82.
WangZQinGZhaoTC.HDAC4: mechanism of regulation and biological functions. Epigenomics2014;
6:139–50
83.
VegaRBMatsudaKOhJBarbosaACYangXMeadowsEMcAnallyJPomajzlCSheltonJMRichardsonJAKarsentyGOlsonEN.Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell2004;
119:555–66
84.
OkaSAgoTKitazonoTZablockiDSadoshimaJ.The role of redox modulation of class II histone deacetylases in mediating pathological cardiac hypertrophy. J Mol Med ( Med)2009;
87:785–91
85.
MatsushimaSKurodaJAgoTZhaiPParkJYXieLHTianBSadoshimaJ.Increased oxidative stress in the nucleus caused by Nox4 mediates oxidation of HDAC4 and cardiac hypertrophy. Circ Res2013;
112:651–63
86.
AgoTLiuTZhaiPChenWLiHMolkentinJDVatnerSFSadoshimaJ.A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell2008;
133:978–93
87.
BacksJSongKBezprozvannayaSChangSOlsonEN.CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy. J Clin Invest2006;
116:1853–64
88.
BacksJWorstBCLehmannLHPatrickDMJebessaZKreusserMMSunQChenLHeftCKatusHAOlsonEN.Selective repression of MEF2 activity by PKA-dependent proteolysis of HDAC4. J Cell Biol2011;
195:403–15
89.
HuangZPChenJSeokHYZhangZKataokaMHuXWangDZ.MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress. Circ Res2013;
112:1234–43
90.
GuptaMPSamantSASmithSHShroffSG.HDAC4 and PCAF bind to cardiac sarcomeres and play a role in regulating myofilament contractile activity. J Biol Chem2008;
283:10135–46
91.
McKinseyTAZhangCLOlsonEN.Identification of a signal-responsive nuclear export sequence in class II histone deacetylases. Mol Cell Biol2001;
21:6312–21
92.
SongKBacksJMcAnallyJQiXGerardRDRichardsonJAHillJABassel-DubyROlsonEN.The transcriptional coactivator CAMTA2 stimulates cardiac growth by opposing class II histone deacetylases. Cell2006;
125:453–66
SucharovCCDockstaderKMcKinseyTA.YY1 protects cardiac myocytes from pathologic hypertrophy by interacting with HDAC5. Mol Biol Cell2008;
19:4141–53
95.
HaCHKimJYZhaoJWangWJhunBSWongCZhengGJ.PKA phosphorylates histone deacetylase 5 and prevents its nuclear export, leading to the inhibition of gene transcription and cardiomyocyte hypertrophy. Proc Natl Acad Sci USA2010;
107:15467–72
96.
SparrowDBMiskaEALangleyEReynaud-DeonauthSKotechaSTowersNSpohrGKouzaridesTMohunTJ.MEF-2 function is modified by a novel co-repressor, MITR. Embo J1999;
18:5085–98
LemonDDHornTRCavasinMAJeongMYHauboldKWLongCSIrwinDCMcCuneSAChungELeinwandLAMcKinseyTA.Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension. J Mol Cell Cardiol2011;
51:41–50
99.
ChengHLMostoslavskyRSaitoSManisJPGuYPatelPBronsonRAppellaEAltFWChuaKF.Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci USA2003;
100:10794–9
100.
AlcendorRRGaoSZhaiPZablockiDHolleEYuXTianBWagnerTVatnerSFSadoshimaJ.Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ Res2007;
100:1512–21
101.
SundaresanNRPillaiVBGuptaMP.Emerging roles of SIRT1 deacetylase in regulating cardiomyocyte survival and hypertrophy. J Mol Cell Cardiol2011;
51:614–8
102.
PlanavilaAIglesiasRGiraltMVillarroyaF.Sirt1 acts in association with PPARalpha to protect the heart from hypertrophy, metabolic dysregulation, and inflammation. Cardiovasc Res2011;
90:276–84
103.
LynnEGMcLeodCJGordonJPBaoJSackMN.SIRT2 is a negative regulator of anoxia-reoxygenation tolerance via regulation of 14-3-3 zeta and BAD in H9c2 cells. FEBS Lett2008;
582:2857–62
SundaresanNRGuptaMKimGRajamohanSBIsbatanAGuptaMP.Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J Clin Invest2009;
119:2758–71
106.
PillaiVBSundaresanNRGuptaMP.Regulation of akt signaling by sirtuins: its implication in cardiac hypertrophy and aging. Circ Res2014;
114:368–78
107.
PillaiVBSundaresanNRKimGGuptaMRajamohanSBPillaiJBSamantSRavindraPVIsbatanAGuptaMP.Exogenous NAD blocks cardiac hypertrophic response via activation of the SIRT3-LKB1-AMP-activated kinase pathway. J Biol Chem2010;
285:3133–44
108.
TsengAHShiehSSWangDL.SIRT3 deacetylates FOXO3 to protect mitochondria against oxidative damage. Free Radic Biol Med2013;
63:222–34
109.
PorterGAUrciuoliWRBrookesPSNadtochiySM.SIRT3 deficiency exacerbates ischemia-reperfusion injury: implication for aged hearts. Am J Physiol Heart Circ Physiol2014;
306:H1602–9
110.
SundaresanNRSamantSAPillaiVBRajamohanSBGuptaMP.SIRT3 is a stress-responsive deacetylase in cardiomyocytes that protects cells from stress-mediated cell death by deacetylation of Ku70. Mol Cell Biol2008;
28:6384–401
111.
ChenCJFuYCYuWWangW.SIRT3 protects cardiomyocytes from oxidative stress-mediated cell death by activating NF-kappaB. Biochem Biophys Res Commun2013;
430:798–803
112.
HaigisMCMostoslavskyRHaigisKMFahieKChristodoulouDCMurphyAJValenzuelaDMYancopoulosGDKarowMBlanderGWolbergerCProllaTAWeindruchRAltFWGuarenteL.SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell2006;
126:941–54
113.
YuJSadhukhanSNoriegaLGMoullanNHeBWeissRSLinHSchoonjansKAuwerxJ.Metabolic characterization of a Sirt5 deficient mouse model. Sci Rep2013;
3:2806
114.
MostoslavskyRChuaKFLombardDBPangWWFischerMRGellonLLiuPMostoslavskyGFrancoSMurphyMMMillsKDPatelPHsuJTHongALFordEChengHLKennedyCNunezNBronsonRFrendeweyDAuerbachWValenzuelaDKarowMHottigerMOHurstingSBarrettJCGuaranteLMulliganRDempleBYancopoulosGDAltFW.Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell2006;
124:315–29
115.
VakhrushevaOSmolkaCGajawadaPKostinSBoettgerTKubinTBraunTBoberE.Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. Circ Res2008;
102:703–10
116.
JonesPSteinkuhlerC.From natural products to small molecule ketone histone deacetylase inhibitors: development of new class specific agents. Curr Pharm Des2008;
14:545–61
117.
MarksPAXuWS.Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem2009;
107:600–8
118.
RodriquezMAquinoMBrunoIDe MartinoGTaddeiMGomez-PalomaL.Chemistry and biology of chromatin remodeling agents: state of art and future perspectives of HDAC inhibitors. Curr Med Chem2006;
13:1119–39
119.
AntosCLMcKinseyTADreitzMHollingsworthLMZhangCLSchreiberKRindtHGorczynskiRJOlsonEN.Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J Biol Chem2003;
278:28930–7
120.
KookHLeporeJJGitlerADLuMMYungWMackayJZhouRFerrariVGruberPEpsteinJA.Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein hop. J Clin Invest2003;
112:863–71
121.
LeeTMLinMSChangNC.Inhibition of histone deacetylase on ventricular remodeling in infarcted rats. Am J Physiol Heart Circ Physiol2007;
293:H968–77
122.
ZhangLQinXZhaoYFastLZhuangSLiuPChengGZhaoTC.Inhibition of histone deacetylases preserves myocardial performance and prevents cardiac remodeling through stimulation of endogenous angiomyogenesis. J Pharmacol Exp Ther2012;
34:285–93
ZhangLXZhaoYChengGGuoTLChinYELiuPYZhaoTC.Targeted deletion of NF-kappaB p50 diminishes the cardioprotection of histone deacetylase inhibition. Am J Physiol Heart Circ Physiol2010;
298:H2154–63
YuLLuMWangPChenX.Trichostatin a ameliorates myocardial ischemia/reperfusion injury through inhibition of endoplasmic reticulum stress-induced apoptosis. Arch Med Res2012;
43:190–6
McKinseyTA.Therapeutic potential for HDAC inhibitors in the heart. Annu Rev Pharmacol Toxicol2012;
52:303–19
129.
McKinseyTA.Targeting inflammation in heart failure with histone deacetylase inhibitors. Mol Med2011;
17:434–41
130.
KeeHJKookH.Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy. J Biomed Biotechnol2011;
2011:928326
131.
McKinseyTA.Isoform-selective HDAC inhibitors: closing in on translational medicine for the heart. J Mol Cell Cardiol2011;
51:491–6
132.
ColussiCIlliBRosatiJSpallottaFFarsettiAGrasselliAMaiACapogrossiMCGaetanoC.Histone deacetylase inhibitors: keeping momentum for neuromuscular and cardiovascular diseases treatment. Pharmacol Res2010;
62:3–10
133.
KangFWQueLWuMWangZLSunJ.Effects of trichostatin a on HIF-1alpha and VEGF expression in human tongue squamous cell carcinoma cells in vitro. Oncol Rep2012;
28:193–9
134.
KaoYHLiouJPChungCCLienGSKuoCCChenSAChenYJ.Histone deacetylase inhibition improved cardiac functions with direct antifibrotic activity in heart failure. Int J Cardiol2013;
168:4178–83
135.
KangSHSeokYMSongMJLeeHAKurzTKimI.Histone deacetylase inhibition attenuates cardiac hypertrophy and fibrosis through acetylation of mineralocorticoid receptor in spontaneously hypertensive rats. Mol Pharmacol2015;
87:782–91
136.
GalloPLatronicoMVGalloPGrimaldiSBorgiaFTodaroMJonesPGallinariPDe FrancescoRCilibertoGSteinkuhlerCEspositoGCondorelliG.Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure. Cardiovasc Res2008;
80:416–24
137.
NebbiosoAManzoFMiceliMConteMManenteLBaldiADe LucaARotiliDValenteSMaiAUsielloAGronemeyerHAltucciL.Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. EMBO Rep2009;
10:776–82
138.
ScognamiglioANebbiosoAManzoFValenteSMaiAAltucciL.HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2. Biochim Biophys Acta2008;
1783:2030–8
139.
LkhagvaBLinYKKaoYHChazoTFChungCCChenSAChenYJ.Novel histone deacetylase inhibitor modulates cardiac peroxisome proliferator-activated receptors and inflammatory cytokines in heart failure. Pharmacology2015;
96:184–91
140.
WilliamsSMGolden-MasonLFergusonBSSchuetzeKBCavasinMADemos-DaviesKYeagerMEStenmarkKRMcKinseyTA.Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes. J Mol Cell Cardiol2014;
67:112–25
141.
Nural-GuvenerHFZakharovaLNimlosJPopovicSMastroeniDGaballaMA.HDAC class I inhibitor, mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activation. Fibrogenesis Tissue Repair2014;
7:10
142.
Nural-GuvenerHZakharovaLFeeheryLSljukicSGaballaM.Anti-Fibrotic effects of class I HDAC inhibitor, mocetinostat is associated with IL-6/Stat3 signaling in ischemic heart failure. Int J Mol Sci2015;
16:11482–99
143.
ZhaoTCChengGZhangLXTsengYTPadburyPF.Inhibition of histone deacetylases triggers pharmacologic preconditioning effects against myocardial ischemic injury. Cardiovasc Res2007;
76:473–81
144.
Demos-DaviesKMFergusonBSCavasinMAMahaffeyJHWilliamsSMSpiltoirJISchuetzeKBHornTRChenBFerraraCScelliniBPiroddiNTesiCPoggesiCJeongMYMcKinseyTA.HDAC6 contributes to pathological responses of heart and skeletal muscle to chronic angiotensin II signaling. Am J Physiol Heart Circ Physiol2014;
307:H252–8
145.
McLendonPMFergusonBSOsinskaHShenuarin BhuiyanMJamesJMcKinseyTARobbinsJ.Tubulin hyperacetylation is adaptive in cardiac proteotoxicity by promoting autophagy. Proc Natl Acad Sci USA2014;
111:E5178–86
146.
McIntyreRLDanielsEGMolenaarsMHoutkooperRHJanssensGE.From molecular promise to preclinical results: HDAC inhibitors in the race for healthy aging drugs. EMBO Mol Med2019;
11:e9854
147.
XieMTangYHillJA.HDAC inhibition as a therapeutic strategy in myocardial ischemia/reperfusion injury. J Mol Cell Cardiol2019;
129:188–92
148.
BagchiRAWeeksKL.Histone deacetylases in cardiovascular and metabolic diseases. J Mol Cell Cardiol2019;
130:151–9
149.
YuWFuYCZhouXHChenCJWangXLinRBWangW.Effects of resveratrol on H(2)O(2)-induced apoptosis and expression of SIRTs in H9c2 cells. J Cell Biochem2009;
107:741–7
150.
BecattiMTaddeiNCecchiCNassiNNassiPAFiorilloC.SIRT1 modulates MAPK pathways in ischemic-reperfused cardiomyocytes. Cell Mol Life Sci2012;
69:2245–60
151.
TannoMKunoAYanoTMiuraTHisaharaSIshikawaSShimamotoKHorioY.Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure. J Biol Chem2010;
285:8375–82
152.
LiYGZhuWTaoJPXinPLiuMYLiJBWeiM.Resveratrol protects cardiomyocytes from oxidative stress through SIRT1 and mitochondrial biogenesis signaling pathways. Biochem Biophys Res Commun2013;
438:270–6
153.
TanLYuJTGuanHS.Resveratrol exerts pharmacological preconditioning by activating PGC-1alpha. Med Hypotheses2008;
71:664–7
154.
SinTKYuAPYungBYYipSPChanLWWongCSYingMRuddJASiuPM.Modulating effect of SIRT1 activation induced by resveratrol on Foxo1-associated apoptotic signalling in senescent heart. J Physiol (Lond)2014;
592:2535–48
155.
BialaATauriainenESiltanenAShiJMerastoSLouhelainenMMartonenEFinckenbergPMullerDNMervaalaE.Resveratrol induces mitochondrial biogenesis and ameliorates Ang II-induced cardiac remodeling in transgenic rats harboring human renin and angiotensinogen genes. Blood Press2010;
19:196–205
156.
PaschalakiKEStarkeRDHuYMercadoNMargaritiAGorgoulisVGRandiAMBarnesPJ.Dysfunction of endothelial progenitor cells from smokers and chronic obstructive pulmonary disease patients due to increased DNA damage and senescence. Stem Cells2013;
31:2813–26
157.
TongCMorrisonAMattisonSQianSBryniarskiMRankinBWangJThomasDPLiJ.Impaired SIRT1 nucleocytoplasmic shuttling in the senescent heart during ischemic stress. Faseb J2013;
27:4332–42
158.
GanoLBDonatoAJPashaHMHearonCMSindlerALSealsDR.The SIRT1 activator SRT1720 reverses vascular endothelial dysfunction, excessive superoxide production and inflammation with aging in mice. Am J Physiol Heart Circ Physiol2014;
307:H1754–63
159.
ShalwalaMZhuSGDasASalloumFNXiLKukrejaRC.Sirtuin 1 (SIRT1) activation mediates sildenafil induced delayed cardioprotection against ischemia-reperfusion injury in mice. PLoS One2014;
9:e86977
160.
PotenzaMASgarraLNacciCLeoVDe SalviaMAMontagnaniM.Activation of AMPK/SIRT1 axis is required for adiponectin-mediated preconditioning on myocardial ischemia-reperfusion (I/R) injury in rats. PLoS One2019;
14:e0210654
161.
KokaSAluriHSXiLLesnefskyEJKukrejaRC.Chronic inhibition of phosphodiesterase 5 with tadalafil attenuates mitochondrial dysfunction in type 2 diabetic hearts: potential role of NO/SIRT1/PGC-1α signaling. Am J Physiol Heart Circ Physiol2014;
306:H1558–68
162.
LinMCHsingCHLiFAWuCHFuYWChengJKHuangB.Rosuvastatin modulates the post-translational acetylome in endothelial cells. Acta Cardiol Sin2014;
30:67–73
